alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 30 studies by DeKosky ST with an author at University of Pittsburgh (US) (page 1 of 2) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Other authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Ginkgo biloba for prevention of dementia: a randomized controlled trial

✓ Peer-reviewed alzhub usefulness score 82 out of 100. JAMA 2008-11-01

In this study, G. biloba at 120 mg twice a day was not effective in reducing either the overall incidence rate of dementia or AD incidence in elderly individuals with normal cognition or those with MCI. 4 key findings →

Participants: 2,587 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Archives of neurology 2003-10-01

The development of MCI is associated with measurements of cognition and depression, racial and constitutional factors, and cerebrovascular disease. 5 key findings →

Design: longitudinal study Participants: 927 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type

✓ Peer-reviewed alzhub usefulness score 65 out of 100. Current Alzheimer research 2005-12-01

The trial did not show efficacy of GbE, however, the lack of decline of the placebo patients may have compromised the sensitivity of the trial to detect a treatment effect. 3 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Inflammatory Biomarkers Predict Domain-Specific Cognitive Decline in Older Adults

✓ Peer-reviewed alzhub usefulness score 64 out of 100. The journals of gerontology. Series A, Biological sciences and medical sciences 2017-06-01

In particular, systemic inflammation, vascular inflammation, and altered endothelial function may play roles in domain-specific cognitive decline of nondemented individuals. 1 key finding →

Design: randomized controlled trial Participants: 1,159 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Mild cognitive impairment, amnestic type: an epidemiologic study

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Neurology 2004-07-01

In this community-based sample, 3 to 4% of nondemented persons met MCI operational criteria; despite increased risk of progressing to dementia, a substantial proportion also remained stable or reverted to normal during follow-up. 3 key findings →

Participants: 1,248 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Association of Brain Amyloid-β With Slow Gait in Elderly Individuals Without Dementia: Influence of Cognition and Apolipoprotein E ε4 Genotype

✓ Peer-reviewed alzhub usefulness score 60 out of 100. JAMA neurology 2017-01-01

Among the 183 study participants, mean (SD) age was 85.5 (3) years, 76 were women (41.5%), and 177 were white (96.7%). 4 key findings →

Design: cross-sectional Participants: 183 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review) [RETIRED]. Report of the Quality Standards Subcommittee of the American Academy of Neurology

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Neurology 2001-05-01

There were insufficient data to make any recommendations regarding cognitive screening of asymptomatic individuals. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The temporal relationship between depressive symptoms and dementia: a community-based prospective study

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Archives of general psychiatry 1999-03-01

Depressive symptoms appeared to be early manifestations, rather than predictors, of Alzheimer disease in this community sample. 3 key findings →

Participants: 1,366 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Prevalence of Alzheimer's disease and other dementias in rural India: the Indo-US study

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Neurology 1998-10-01

In this population, the prevalence of AD and other dementias was low, increased with age, and was not associated with gender or literacy. 5 key findings →

Participants: 5,126 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Ten-year incidence of dementia in a rural elderly US community population: the MoVIES Project

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Neurology 2000-03-01

Incidence rates of all dementias and of AD increased with age; men and those with lesser education had higher rates of possible/incipient dementia (CDR = 0.5) in this community. 5 key findings →

Participants: 1,298 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Neurology 2007-05-01

These results strongly support the concept that synapse loss is a structural correlate involved very early in cognitive decline in mild Alzheimer disease (mAD) and supports mild cognitive impairment as a transitional stage between mAD and no cognitive impairment. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 54 out of 100. The Journal of neuropsychiatry and clinical neurosciences 2003-01-01

This cross-sectional study examines relationships among the constellation of psychiatric syndromes in Alzheimer's disease (AD) as a function of dementia severity in 1155 patients with probable AD. 4 key findings →

Design: cross-sectional Participants: 1,155 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Pathways linking late-life depression to persistent cognitive impairment and dementia

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Dialogues in clinical neuroscience 2008-01-01

There is a strong association between late-life depression, cognitive impairment, cerebrovascular disease, and poor cognitive outcomes, including progressive dementia, especially Alzheimer's disease. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1998-06-01

Serotonin (5-HT) neuron and neurotransmitter loss in normal aging and neuropsychiatric diseases of late life may contribute to behavioral changes commonly observed in the elderly population. 4 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Journal of neurology, neurosurgery, and psychiatry 2002-03-01

The short and long term effects of CEIs were evaluated in 135 patients with probable Alzheimer's disease relative to 135 patients who were never exposed to CEIs matched by age, education, duration of the symptoms, and cognitive status. 4 key findings →

Participants: 135 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Archives of neurology 2009-01-01

These findings suggest that either microglial activation is limited to later stages of severe AD or [11C](R)-PK11195 is too insensitive to detect the level of microglial activation associated with mild to moderate AD. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed